Ameliorating effects of an intestinal disaccharidase inhibitor, AO-128, in streptozotocin-diabetic rats

The ameliorating activity of an intestinal disaccharidase inhibitor, AO-128, was evaluated in rats with diabetes of varying severity. Diabetic rats were produced by injecting 120mg/kg streptozotocin (STZ) into 1.5- and 5-day-old neonates. From the age of 9 week, the rats were given AO-128 as a dieta...

Full description

Saved in:
Bibliographic Details
Published inNihon Eiyō, Shokuryō Gakkai shi Vol. 45; no. 1; pp. 33 - 38
Main Authors Odaka, H. (Takeda Chemical Industries Ltd., Osaka (Japan)), Matsuo, T
Format Journal Article
LanguageJapanese
Published Japan Society of Nutrition and Food Science 1992
Subjects
DIABETE
DIABETES
DIETA TERAPEUTICA
disacchardidase inhibitor
ENZYME INHIBITORS
glucose tolerance
INHIBIDORES DE ENZIMAS
INHIBITEUR D'ENZYME
INSULIN
insulin response to glucose
INSULINA
INSULINE
RAT
RATA
RATS
REGIME ALIMENTAIRE THERAPEUTIQUE
streptozotocin diabetic rat
THERAPEUTIC DIETS
Online AccessGet full text

Cover

More Information
Summary:The ameliorating activity of an intestinal disaccharidase inhibitor, AO-128, was evaluated in rats with diabetes of varying severity. Diabetic rats were produced by injecting 120mg/kg streptozotocin (STZ) into 1.5- and 5-day-old neonates. From the age of 9 week, the rats were given AO-128 as a dietary admixture at a dose of 5 mg/100g of diet for 28 days. AO-128 normalized the basal levels of plasma glucose, which were elevated, and both glucose tolerance and insulin response, which were impaired in animals injected with STZ at the age of 1.5 days. On the other hand, animals administered STZ at the age of 5 days showed overt diabetes syndrome including features such as hyperglycemia, hypoinsulinemia, hyperphagia, polydipsia, polyuria and glucosuria. AO-128 partly ameliorated these diabetic symptoms.
Bibliography:L70
L51
9400818
ISSN:0287-3516
1883-2849
DOI:10.4327/jsnfs.45.33